X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16) 16
hematology (13) 13
beer (12) 12
biochemistry (12) 12
chemistry (12) 12
compositions or test papers therefor (12) 12
condition-responsive control in microbiological orenzymological processes (12) 12
enzymology (12) 12
measuring or testing processes involving enzymes, nucleicacids or microorganisms (12) 12
metallurgy (12) 12
microbiology (12) 12
mutation or genetic engineering (12) 12
processes of preparing such compositions (12) 12
spirits (12) 12
vinegar (12) 12
wine (12) 12
index medicus (10) 10
multiple myeloma - pathology (10) 10
female (9) 9
middle aged (9) 9
multiple myeloma (9) 9
multiple myeloma - drug therapy (9) 9
treatment outcome (9) 9
adult (8) 8
aged (8) 8
male (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
multiple myeloma - genetics (7) 7
aged, 80 and over (6) 6
chemotherapy (6) 6
multiple myeloma - mortality (6) 6
oncology (6) 6
thalidomide - analogs & derivatives (6) 6
lenalidomide (5) 5
thalidomide - administration & dosage (5) 5
animals (4) 4
bortezomib (4) 4
dexamethasone - administration & dosage (4) 4
disease-free survival (4) 4
mice (4) 4
relapsed (4) 4
retrospective studies (4) 4
survival (4) 4
t (4) 4
thalidomide (4) 4
therapy (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
cell line, tumor (3) 3
cyclophosphamide (3) 3
cyclophosphamide - administration & dosage (3) 3
hematology, oncology and palliative medicine (3) 3
multiple myeloma - therapy (3) 3
phosphorylation (3) 3
plus dexamethasone (3) 3
prednisone (3) 3
protein-tyrosine kinases (3) 3
receptor, fibroblast growth factor, type 3 (3) 3
recurrence (3) 3
salvage therapy (3) 3
steroids (3) 3
survival rate (3) 3
alternate-day prednisone (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
apoptosis - drug effects (2) 2
article (2) 2
cancer (2) 2
care and treatment (2) 2
combination (2) 2
dexamethasone (2) 2
dexamethasone - therapeutic use (2) 2
diagnosis (2) 2
drug administration schedule (2) 2
drug resistance, neoplasm (2) 2
efficacy (2) 2
expression (2) 2
gene expression profiling (2) 2
human necessities (2) 2
hygiene (2) 2
immunology (2) 2
impact (2) 2
investigating or analysing materials by determining theirchemical or physical properties (2) 2
kaplan-meier estimate (2) 2
measuring (2) 2
medical or veterinary science (2) 2
melphalan (2) 2
multiple myeloma - complications (2) 2
multiple myeloma - diagnosis (2) 2
mutation (2) 2
neoplasm proteins - genetics (2) 2
neoplasm recurrence, local (2) 2
neoplasm staging (2) 2
oligonucleotide array sequence analysis (2) 2
outcomes (2) 2
physics (2) 2
prednisone - administration & dosage (2) 2
preparations for medical, dental, or toilet purposes (2) 2
receptors, fibroblast growth factor - genetics (2) 2
refractory (2) 2
refractory multiple myeloma (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Communications, ISSN 2041-1723, 2017, Volume 8, Issue 1, p. 15086
The requirement for bone-marrow aspirates for genomic profiling of multiple myeloma poses an obstacle to enrolment and retention of patients in clinical... 
CELL LUNG-CANCER | DIAGNOSIS | IMPACT | TRAMETINIB | MULTIDISCIPLINARY SCIENCES | MUTATIONS | SAMPLES | PLASMA-CELLS
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2015, Volume 168, Issue 1, pp. 46 - 54
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2013, Volume 162, Issue 4, pp. 483 - 488
Summary Involvement of the central nervous system (CNS) in multiple myeloma (MM) is a rare complication, with reported survival of <6 months. This report... 
multiple myeloma | immunomodulatory drugs | leptomeningeal | intrathecal chemotherapy | central nervous system | Immunomodulatory drugs | Intrathecal chemotherapy | Central nervous system | Multiple myeloma | Leptomeningeal | PLASMA | BORTEZOMIB | THALIDOMIDE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Pyrazines - administration & dosage | Salvage Therapy | Central Nervous System - pathology | Male | Transplantation, Autologous | Cisplatin - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Retrospective Studies | Boronic Acids - administration & dosage | Radiotherapy, Adjuvant | Spine - pathology | Multiple Myeloma - surgery | Orbit - pathology | Doxorubicin - administration & dosage | Injections, Spinal | Bortezomib | Meninges - pathology | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Thalidomide - administration & dosage | Cranial Irradiation | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Aged | Multiple Myeloma - radiotherapy | Thalidomide - therapeutic use | Immunologic Factors - therapeutic use | Chemotherapy | Nuclear radiation | Cancer
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 5821 - 5821
Abstract Background: A second (salvage) ASCT has frequently been offered to MM patients with relapsed disease who experience benefit from the first procedure.... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2008 - 2008
Abstract Introduction: Bortezomib-containing regimens (BCRs) have been the standard frontline approach for the treatment of transplant ineligible multiple... 
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 04/2019, Volume 19, Issue 4, pp. e195 - e203
The combination of lenalidomide and dexamethasone (Len-Dex) is an established regimen for patients with relapsed or refractory myeloma. To prolong the benefit... 
Refractory | Cyclophosphamide | Lenalidomide | Relapsed | Multiple myeloma
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 3457 - 3457
Abstract Introduction: The optimal management of multiple myeloma (MM) patients (pts) with t(4;14) is not certain. Before the introduction of novel agents, the... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 2137 - 2137
Abstract Introduction Maintenance therapy after first-line ASCT improves outcomes, although virtually all pts eventually relapse. The pattern of first relapse... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1842 - 1842
Abstract Introduction The lenalidomide + dexamethasone combination (Len-dex) is an established regimen for myeloma patients (pts) with relapsed or refractory... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 3176 - 3176
Abstract Background: Recent analyses have suggested that newly diagnosed multiple myeloma (MM) patients with the high-risk (HR) chromosomal abnormalities del... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e19532 - e19532
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 2019 - 2019
Abstract Introduction With routine use of autologous stem cell transplantation (ASCT) and novel agents, survival of patients with multiple myeloma (MM) has... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4756 - 4756
Abstract Background: Although overall MM survival has improved in recent years, there is significant heterogeneity, with some patients achieving survival over... 
Journal Article
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, ISSN 2152-2650, 04/2019, Volume 19, Issue 4, pp. E195 - E203
Triplet therapy has yielded superior results compared with doublet therapy in recent studies of relapsed myeloma. An alternative approach, in an attempt to... 
Lenalidomide | Relapsed | Multiple myeloma | LOW-DOSE CYCLOPHOSPHAMIDE | THALIDOMIDE | COMBINATION | CHEMOTHERAPY | Refractory | Cyclophosphamide | PREDNISONE | THERAPY | PLUS DEXAMETHASONE | ONCOLOGY | REGULATORY T-CELLS | HEMATOLOGY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.